Form 10-Q GALECTIN THERAPEUTICS For: Sep 30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. META
5. SPY
6. ANT
7. INTC
8. JBLU
9. NVDA
10. AAPL

Go back to Form 10-Q GALECTIN THERAPEUTICS For: Sep 30

Galectin Therapeutics (GALT) Tops Q3 EPS by 10c

November 10, 2014 8:14 AM EST

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).

The Company also provided an update on its development program.

According to Peter Traber, M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics, "In the past three months, we have continued progress in our development program. We were pleased to have data from cohorts 1 and 2, as well as, interim data from nine completed patients from cohort 3 of our Phase 1 clinical trial of GR-MD-02, our patent-protected proprietary galectin inhibitor, in patients with NASH with advanced... More